Rapamycin for the treatment of lymphangioleiomyomatosis
View Patent ↗The present invention relates to methods and compositions for treating lymphangioleiomyomatosis in a human subject in need of such treatment. The methods comprise administering to the subject via inhalation an aerosol composition comprising rapamycin or a prodrug or derivative (including analog) thereof.
1. A pharmaceutical dry powder composition for pulmonary delivery comprising microparticles of sirolimus, particles of a carrier, and one or more optional excipients, wherein the microparticles of sirolimus have a mean diameter of from 1 to 5 microns and the sirolimus is the only therapeutic agent in the composition.
2. The composition of claim 1 , wherein the carrier is selected from the group consisting of arabinose, glucose, fructose, ribose, mannose, sucrose, trehalose, lactose, maltose, starches, dextran, mannitol, lysine, leucine, isoleucine, dipalmitylphosphatidylcholine, lecithin, polylactic acid, poly(lactic-co-glutamic) acid, and xylitol, or mixtures of any of the foregoing.
3. The composition of claim 2 , wherein the carrier comprises or consists of a blend of two different carriers, a first carrier and a second carrier.
4. The composition of claim 3 , wherein the carrier consists of a blend of two different lactose carriers.
5. The composition of claim 3 , wherein the first carrier consists of particles having diameters ranging from about 30-100 microns and the second carrier consists of particles having diameters of less than 10 microns.
6. The composition of claim 5 , wherein the ratio of the two different carriers is in the range of from 3:97 to 97:3.
7. The composition of claim 1 , wherein the one or more optional excipients is present and is selected from a phospholipid and a metal salt of a fatty acid.
8. The composition of claim 7 , wherein the phospholipid is selected from dipalmitylphosphatidylcholine and lecithin.
9. The composition of claim 7 , wherein the metal salt of a fatty acid is magnesium stearate.
10. The composition of claim 9 , wherein the optional excipient or excipients is present and the magnesium stearate is coated on the carrier particles.
11. The composition of claim 1 , wherein the amount of sirolimus is an amount effective to inhibit the biological activity of mTORC1.
12. The composition of claim 11 , wherein the amount of sirolimus is an amount effective to inhibit the phosphorylation of the S6 protein.
13. The composition of claim 1 , wherein the amount of sirolimus is an amount effective to achieve a respirable dose of from 5 to 400 micrograms delivered to the lung.
14. The composition of claim 1 , wherein the composition has a fine particle fraction (FPF) greater than 20% with a corresponding fine particle dose (FPD) ranging from 10 micrograms to 500 micrograms following 1 to 12 months of storage.
15. The composition of claim 1 , where the composition is adapted for once daily administration.
16. The composition of claim 1 , wherein the carrier consists of a blend of two different lactose carriers, the first carrier consists of particles having average diameters ranging from about 30-100 microns and the second carrier consists of particles having average diameters of less than 10 microns and the ratio of the two different carriers is about 97:3 to 3:97.
17. A unit dosage form comprising the composition of claim 1 , wherein the amount of sirolimus is from 50 to 250 micrograms.
18. The unit dosage form of claim 17 , wherein the dosage form is a capsule suitable for use in a dry powder inhaler device.
19. A method for treating lymphangioleiomyomatosis in a human subject in need of such treatment, the method comprising administering to the subject via inhalation the composition of claim 1 .